



27 **Abstract**

28 **Purpose:** The minimal clinically important difference (MCID) of a patient-reported outcome (PRO)  
29 represents the threshold value of the change in the score for that PRO. It is deemed to have an  
30 important implication in clinical management. This study was performed to evaluate the clinical  
31 significance of chronic disease self-management (CDSM) for patients with chronic heart failure based  
32 on the MCID of the chronic heart failure - PRO measure (CHF-PROM).

33 **Methods:** A multicenter, prospective cohort study of 555 patients with heart failure were enrolled from  
34 July 2018. Advice of CDSM was provided in written form at discharge to all patients. Information  
35 regarding CHF-PROM and CDSM were collected during follow-up. Multilevel models were applied to  
36 dynamically evaluate the effects of CDSM for CHF-PROM scores, as well as its physical and  
37 psychological domains. MCID changes of the PRO were introduced and compared with  $\beta$  values of  
38 CDSM obtained from the multi-level models to further evaluate the clinical significance.

39 **Results:** Scores for CHF-PROM improved significantly after discharge. The multilevel models showed  
40 that a regular schedule, avoidance of over-eating, a low-sodium diet and exercise increased scores on  
41 CHF-PROM. Compared with the MCID, avoidance of over-eating (12.39 vs. 9.75) and maintenance of  
42 a regular schedule often (10.98 vs. 9.75), and exercise almost every day (11.36 vs. 9.75) reached  
43 clinical significance for the overall summary. Avoidance of over-eating (5.88 vs. 4.79) and a regular  
44 schedule almost every day (4.96 vs. 4.79) reached clinical significance for the physical scores.  
45 Avoidance of over-eating half of the time (5.26 vs. 4.87) and a regular schedule almost every day (5.84  
46 vs. 4.87) demonstrated clinical significance for the psychological scores.

47 **Conclusions:** This study observed an association of avoidance of over-eating and maintenance of a  
48 regular schedule with the improvement of CHF-PROM. It provides further evidence for management  
49 of heart failure.

50 **Trial registration:** 2018LL128, Registered January 2, 2018- Prospective registered,  
51 <http://www.sxmu.edu.cn/>.

52 **Key words:** patient-reported outcome; chronic heart failure; chronic disease self-management;  
53 multilevel model; minimal clinically important difference

54

55 **1 Introduction**

56 Chronic heart failure (CHF) affects 1.5% to 2.0% of the adult population in developed countries  
57 [1] and 0.9% of the population aged 35 to 74 years in China [2]. CHF is the most severe stage of heart  
58 disease and has poor outcomes [3]. Therefore, close attention has been paid to evaluation and  
59 improvement of the endpoints of CHF.

60 Patient-reported outcomes (PROs) which reflect patient-centered quality of life are among the  
61 most crucial endpoints as recommended by the United States Food and Drug Administration, the  
62 International Association for Pharmaceutical Economics and Outcome Research, and the International  
63 Society for Quality of Life Research [4]. In recent years, researchers have begun to use PROs to  
64 evaluate the effects of intervention measures in patients with chronic diseases, including CHF [5].  
65 Chronic disease self-management (CDSM), which is recommended by the European Society of  
66 Cardiology, can improve the outcomes of patients with heart failure [6]. However, the effects of CDSM  
67 on PROs are highly heterogeneous among these patients [7,8].

68 Some deficiencies of previous studies may have interfered with the results. First, multi-point  
69 dynamic follow-up can accurately reflect the real-time changes in the disease. However, traditional  
70 prognostic analysis methods (e.g., logistic regression and Cox regression) are not suitable for these  
71 non-independent data. Second, evaluation of the effect of CDSM on patients with CHF has been mostly  
72 dependent upon the statistical significance [7,8], the professional clinical sense has largely been  
73 ignored. The minimal clinically important difference (MCID) of PROs represents the threshold value  
74 of the clinical change in the score. The MCID is deemed to have an important implication in clinical  
75 management. Therefore, in the present study, we applied a multi-level model to analyze the roles of  
76 CDSM based on the MCID of PROs to obtain more reliable and meaningful evidence.

77

78 **2 Methods**

79 **2.1 Participants**

80 Patients from three medical centers in the Shanxi province of China were enrolled from July 2018  
81 to December 2019 according to predefined inclusion and exclusion criteria. The inclusion criteria were:  
82 age  $\geq 18$  years; diagnosed with HF according to current guidelines [3]; New York Heart Association

83 (NYHA) functional class II-IV; and receipt of HF therapy in the past month. Patients who experienced  
84 acute cardiovascular events except acute onset of CHF in the past 2 months, had a life expectancy of <  
85 1 year, could not understand or complete the questionnaire due to language barriers or intellectual  
86 disabilities, and those who refused to participate in this project were excluded.

## 87 **2.2 Procedure and data collection**

88 During hospitalization, information regarding baseline data, the self-administered questionnaire,  
89 and CHF-PROM scores were collected. The advice of CDSM was provided in written form to all of the  
90 participants at discharge. All participants were followed-up at 1, 3, and 6 months after discharge in  
91 face-to-face consultations or telephone follow-up to obtain information regarding the self-administered  
92 questionnaire and CHF-PROM scores [9]. To ensure quality, all questionnaires were administered by  
93 professionally trained individuals.

94 CDSM included medication use, a regular schedule, keeping warm, dietary instructions, health  
95 education, smoking cessation, temperance, and exercise. Dietary instructions included a low-sodium  
96 diet (LSD), a low-fat diet, and the avoidance of over-eating. Among these strategies, a regular schedule  
97 was defined as maintaining relatively fixed sleep and wake times, and an LSD as intaking < 5 g of salt  
98 per day.

99 Baseline information included patient's age, sex, height, weight, marital status, education, annual  
100 income, family history of cardiovascular disease, NYHA functional class, blood pressure, and  
101 complications. The Charlson Comorbidity Index (CCI) was applied to assess complications [10].

102 The self-administered questionnaire was developed to assess CDSM. The questionnaire contained  
103 all strategies provided at discharge as mentioned above, with responses scored on a 5-point Likert, as  
104 follows: 0 (never happens); 1 (happens occasionally); 2 (happens half of the time); 3 (happens often);  
105 and 4 (happens every day).

106 The CHF-PROM developed by the authors' research group was applied in this study. This  
107 questionnaire contains 57 items, 12 subdomains, and 4 domains, which consisted of physical,  
108 psychological, social, and therapeutic domains [9]. Patients responded to each item on a 5-point Likert  
109 scale to reflect how often they had experienced each issue during the past 2 weeks (0 = never, 1 =  
110 occasionally, 2 = about half of the time, 3 = often, and 4 = almost every day). All responses were  
111 transformed into scores based on the following principle: positively scored items were recorded as the

112 original score plus 1, while negatively scored items were recorded as 5 minus the original score. After  
113 that, overall summary (OS), physical scores (PHYS) and psychological scores (PSYS) of CHF-PROM  
114 were calculated by adding scores of the corresponding items. Items were described as previously [9].  
115 The structure of the CHF-PROs is shown in supplementary 2.

### 116 **2.3 Statistical analysis**

117 Continuous variables are expressed as mean  $\pm$  standard deviation (SD) or median (interquartile  
118 range). Cronbach's  $\alpha$  coefficient was applied to assess the data quality of the CHF-PROM. The  
119 variables that missing more than 15 percent were deleted. In addition, we added the data missing less  
120 than 15 percent with missForest. The backward method was used for statistically significant variables  
121 ( $P < 0.1$ ). Univariate analysis of variables and calculation of MCID were performed using SPSS  
122 version 25.0 (IBM Corporation, Armonk, NY, USA). Further multilevel model assumptions were  
123 confirmed through analysis of residuals generated by MLwiN version 3.0 software (Centre for  
124 Multilevel Modelling, University of Bristol, Bristol, United Kingdom).

#### 125 **Multilevel model**

126 The multilevel model, which can handle repeated measures data, was applied to assess the effect  
127 of CDSM strategies to the OS of CHF-PROM. The main concept of this model is to estimate variance  
128 at each level and consider the effect of the explanatory variables on the variance to estimate the  
129 regression coefficient effectively [11]. The model was constructed as follows:

$$130 \quad Y_{ij} = \beta_{0j} + \sum_{i=1} \beta_{ij}X_{ij} + e_{ij} \quad (1)$$

$$131 \quad \beta_{0j} = \beta_0 + u_{0j} \quad (2)$$

$$132 \quad \beta_{ij} = \beta_j + u_{ij} \quad (3)$$

133  $Y_{ij}$  represents OS of CHF-PROM taken from the  $i$ th person;  $e_{ij}$  is the residual of the first level;  
134  $\beta_{0j}$  is the coefficient variable, which could be formulated by equation 2;  $\beta_0$  and  $\beta_j$  stand for fixed  
135 parameters representing the average of the intercept and slope, respectively; and  $u_{0j}$  and  $u_{ij}$   
136 represent interindividual variability in intercepts and slopes via random effects. Maximum likelihood  
137 estimates can be computed from the covariance matrix.

138

139 **Multivariate multilevel model**

140 The multivariate multilevel model was fitted to assess CDSM strategies on PHYS, PSYS [11].

141 The multivariate variance components model was constructed as follows:

142 
$$Y_{itk} = \sum_k D_k (\beta_{0ik} + \beta_{1ik} + e_{itk}) \quad (4)$$

143 
$$\beta_{0ik} = \beta_{0k} + u_{0ik} \quad (5)$$

144 
$$\beta_{1ik} = \beta_{1k} + u_{1ik} \quad (6)$$

145 In the equation above,  $Y_{itk}$  represents the vector of two outcome measurements, taken from the  $i$   
146 th person at time  $t$ ;  $D_k$  is a pseudo variable, with a unique pseudo variable for each outcome; the  $k$   
147 response variable,  $\beta_{0ik}$  is the overall intercept for person  $i$ ;  $\beta_{1ik}$  denotes a patient-specific slope; and  
148  $e_{itk}$  is residual error at time  $t$  for person  $i$ .

149 In the present study, model 1 was the null model. Time was added to model 1 as an explanatory  
150 variable to establish model 2, which was used to study the effect of time on variables. Model 3 was  
151 constructed when baseline information and CDSM situation of participants were included in model 2.

152 **MCID**

153 Although  $P < 0.05$  is often considered to be the criterion for evaluating the effectiveness of an  
154 intervention in PROs or QoL, the  $P$  value merely represents statistical significance. In our study, MCID  
155 was introduced to analyze its clinical significance to determine more effective CDSM strategies. ES of  
156 the distribution method was applied to calculate MCID according to characteristics of the current CHF-  
157 PROM data [12, 13]. ES was formulated as follows:

158 
$$ES = \frac{\bar{x}_1 - \bar{x}_0}{\sqrt{\sum(x_0 - \bar{x}_0)^2 / (n-1)}} \quad (7)$$

159 In the equation above,  $x_0$  represents baseline scores of patients.  $\bar{x}_0$  represents the average  
160 baseline scores of individuals, and  $\bar{x}_1$  is the average follow-up scores of individuals. In our study, a  
161 moderate effect of 0.5 was used as the effect size statistic to estimate MCID.

162 Finally,  $\beta$  values of the multi-level model were compared with MCID. The first level of the  
163 variables was considered “0”, and multiplied the  $\beta$  value by the grade of levels minus “1”. The  
164 corresponding grade of variables up to MCID was defined as reaching clinical significance.

165

166 **3 Results**

167 **3.1 Sample characteristics**

168 Baseline characteristics of the patients are shown in Table 1. A total of 555 patients with CHF,  
169 with a mean  $\pm$  SD age of  $67.86 \pm 14.58$  years, was enrolled. Of these patients, 44.14% were female.  
170 67.9% of them suffered from ischemic heart disease. Most participants were married (80.72%) and had  
171 a low level of education (below secondary high school [72.61%]), and 49.19% and 47.75% had a low  
172 and medium annual income, respectively.

173 Insert Table1 here

174 **3.2 CHF-PROM scores**

175 Cronbach's  $\alpha$  coefficients for the physical domain, psychological domain, social domain,  
176 therapeutic domain, and overall scale were 0.893, 0.936, 0.835, 0.828, and 0.908, respectively. The  
177 mean CHF-PROM scores for OS, PSYS, and PHYS were  $222.84 \pm 23.18$ ,  $59.40 \pm 10.84$ , and  
178  $89.60 \pm 12.90$ , respectively. The scores were lowest during hospitalization, and improved significantly  
179 after discharge. The results are shown in Table 2.

180 Insert Table2 here

181 **3.3 Multilevel model of CDSM on CHF-PROM**

182 Three model levels were applied to assess CDSM strategies on OS of CHF-PROM; the results are  
183 summarized in Table 3. Model 1 demonstrated that the variance of level 2 (individual level) was  
184 statistically significant. It indicated that the data had aggregation and hierarchical structure at the  
185 individual level. Model 3 demonstrated that a regular schedule, avoidance of over-eating, an LSD and  
186 exercise improved OS in CHF-PROM. For each additional grade of the measures, OS increased by  
187 3.66, 4.13, 1.71, and 2.84, respectively. Advanced age, female sex, and increased NYHA functional  
188 class were negatively correlated. A -2log likelihood was applied as the goodness fit evaluation index.  
189 The -2log likelihood of model 2 was smaller than model 1 (16159.17 versus [vs.] 16844.48); more  
190 specifically, the goodness fit of model 2 was better than model 1. For the same reason, model 3 had  
191 better goodness fit than model 2 (15651.74 vs. 16159.17). The residual distribution diagram is close to  
192 a straight line. Therefore, it indicated that the assumption of normal distribution of each level residuals  
193 was reasonable (Fig. 1).

194

Insert Table3 here

195

Insert Fig. 1 here

196

197

198

199

200

201

202

203

204

205

206

207

A two-variable, three-level model was applied to analyze the roles of CDSM strategies to PHYS and PSYS, the results are presented in Table 4. Model 1 demonstrated that the variance of level 3 (individual level) was statistically significant. It indicated that the data had aggregation and hierarchical structure at the individual level. According to the model, a regular schedule, avoidance of over-eating, an LSD and exercise increased PHYS and PSYS. For each additional grade of the measures, PHYS increased by 1.24, 1.96, 0.86, and 1.18 and PSYS increased by 1.46, 2.63, 0.76, and 0.55. In addition, taking angiotensin-converting enzyme inhibitors or angiotensin receptor blocker decreased the PSYS of patients with CHF. Advanced age, female sex, increased NYHA functional class and CCI were negatively correlated with PHYS and PSYS. A -2log likelihood demonstrated that the goodness fit of model 2 was better than model 1 (26155.51 vs. 27286.37), and model 3 was better than model 2 (25458.50 vs. 26155.51). The residual distribution diagram is close to a straight line. Therefore, it indicated that the assumption of normal distribution of each level residuals was reasonable (Fig. 2).

208

Insert Table4 here

209

Insert Fig. 2 here

210

### **3.4 MCID and its interpretation to the multilevel model**

211

212

213

214

The MCIDs for the scores of each dimension and domain and the total scale are shown in Table 5. The MCIDs for OS, PHYS, and PSYS were 9.75, 4.79, and 4.87, respectively. This indicates that scores for the CHF-PROM, physical domain, and psychological domain that changed by at least 9.75, 4.79, and 4.87 points were considered clinically significant.

215

216

217

218

219

Compared with MCID, the avoidance of over-eating of grade 4 and 5, regular schedule of grade 4 and 5 and exercise of grade 5 reached clinical significance for OS. Avoidance of over-eating of grade 4 and 5 and a regular schedule of grade 5 reached clinically significance for PHY. Regarding the PSY, avoidance of over-eating of grade 3, 4 and 5 and a regular schedule of grade 5 also demonstrated the clinical significance.

220

Insert Fig. 3 here

221

## 222 **4 Discussion**

223 The present study assessed the impact of several types of CDSM strategies on CHF-PROM scores.  
224 Here, we confirmed that maintenance of a regular schedule, avoidance of over-eating, an LSD and  
225 exercise could improve CHF-PROM scores in patients with CHF. Among these, however, only a  
226 regular schedule and avoidance of over-eating reached clinical significance based on the MCID of  
227 CHF-PROM. Compared to previous studies, various strategies were considered and changes in these  
228 over time were assessed. Moreover, based on statistical significance, clinical significance was  
229 emphasized by virtue of the MCID.

230 The characteristics of patients with CHF have an impact on PROs. In our study, a high NYHA  
231 functional class, female sex, and advanced age decreased the OS in CHF-PROM, as well as PHYS and  
232 PSYS. Moreover, CCI was negatively correlated with PHYS and PSYS. These factors have already  
233 been shown as influence factors of PROs in patients with CHF in previous studies [10, 14-16]. We used  
234 multivariate statistical methods to avoid the influence of these covariates on the results; thus, we were  
235 able to obtain CDSM strategies that improved CHF-PROM more accurately.

236 Results of our study demonstrated that maintaining a regular schedule improved CHF-PROM. The  
237 same result was obtained in previous studies using other PRO scales of HF. Broström et al found that  
238 sleep disturbances affected virtually all dimensions of the Short-form 36 and Kansas City  
239 Cardiomyopathy Questionnaire (KCCQ) for patients with CHF, while daytime sleepiness decreased  
240 total Minnesota Living with Heart Failure (MLWHF) scores, as well as scores on physical and  
241 emotional subscales [17]. Liu et al reported that poor sleepers had significantly lower scores in  
242 physical, psychological, and social domains of the World Health Organization Quality of Life-BREF  
243 (WHOQOL-BREF) scale [18]. Sleep disorders in patients with CHF are caused by sleep-disordered  
244 breathing, depression, and HF symptoms such as dyspnea and dysrhythmias [19]. These investigations  
245 were cross-sectional studies, and dynamic changes in sleeping habits and PROs were not observed. Our  
246 study applied a multilevel model to introduce time as a variable. A prospective cohort study using one-  
247 way repeated measures analysis reported that exercise and cognitive behavioral therapy may improve  
248 sleep quality and QoL in patients with CHF [20]. In our study, patients were informed that they should  
249 maintain a regular routine, regardless of the strategy they used. The results of our study emphasize the  
250 importance of a regular schedule in patients with CHF. Moreover, only patients who maintained a

251 regular schedule virtually every day achieved MCID, reflecting that it is necessary for patients to be  
252 compliant with physician recommendations.

253 Over-eating often relies on patient perception and lacks objective indicators for evaluation. As  
254 such, few studies have extensively investigated this factor. Our study unexpectedly found that  
255 avoidance of over-eating dramatically decreased OS, as well as PHYS and PSYS in CHF-PROM.  
256 Research presented at the American Heart Association meeting in 2000 found that a single large meal  
257 led to a fourfold increase in heart attacks within 2 h of the meal [21]. A rich diet burdens the heart due  
258 to diversion of the circulation to the gastrointestinal tract following a meal. Such a diversion increases  
259 cardiac blood and causes further stress on the heart. Moreover, acute fluctuations in blood pressure and  
260 heart rate occur after a rich meal and lead to further damage to the heart [22]. If an individual with CHF  
261 consumed a large, high-salt meal, acute decompensation could even occur [23]. The avoidance of over-  
262 eating may improve CHF-PROM by decreasing the incidence of these types of adverse events. This  
263 result provides new evidence supporting the management of CHF and direction for future studies.

264 An LSD was recommended by the 2016 European Society of Cardiology Guidelines for CHF [3].  
265 In the present study, we confirmed that an LSD increased OS, PHYS, and PSYS of CHF-PROM.  
266 Previous studies and the ongoing Geriatric Out-of-Hospital Randomized Meal Trial in Heart Failure  
267 (GOURMET-HF) study applied the KCCQ summary score as an indicator of QoL outcome and drew  
268 the same conclusion as that in our study [24-26]. Regarding PHYS, the reason for the increase may be  
269 that an LSD improved symptoms and signs of CHF [27, 28] and promoted exercise tolerance in  
270 patients [28]. However, few studies have focused on the relationship between LSD and psychological  
271 states. More studies are needed to confirm this and the mechanism also remains to be further  
272 elucidated. Adherence to an LSD has also been noted by researchers. Chung et al confirmed that  
273 patients who adhered to an LSD perceived more benefits than those who were non-adherent [29]. All of  
274 the research above focused exclusively on statistical significance and ignored clinical significance.  
275 When MCID was introduced, it did not reach clinical significance, regardless of a patient's adherence  
276 to an LSD in this study. This also may be because some patients did not accurately calculate the  
277 amount of salt they ate at home. More stringent studies and investigations examining clinical  
278 significance are needed in the future.

279 Regular aerobic exercise is encouraged in patients with HF to improve functional capacity and  
280 symptoms, as per guideline recommendations [3]. Studies have shown that exercise can reduce all-  
281 cause mortality and readmission for patients with CHF; however, the effects of exercise on QoL remain  
282 uncertain [30]. A recent meta-analysis confirmed that exercise improved both exercise capacity and  
283 QoL compared with the no-exercise control group at the 12-month follow-up, but with weaker  
284 evidence for a treatment effect at the 6-month follow-up [31]. Our study demonstrated that exercise  
285 improved CHF-PROM. This is consistent with previous studies and provides the new evidence for the  
286 effect at the 6-month follow-up.

287 The findings of this study should be interpreted in light of its limitations. First, all advice adopted  
288 in this study was beneficial to strategies for patients with CHF. Based on ethical considerations, we  
289 provided all participants with advice when they were discharged; as such, there was no control group.  
290 It revealed that the causal effect was not as strong as that from a randomized controlled trial. We will  
291 use randomized controlled trial design in future research to assess one of the meaningful strategies in  
292 this study. Second, although this was a multicenter study, all patients were from the Shanxi Province of  
293 China and, as such, the findings may be regionally biased. Larger-scale studies are needed in the future  
294 to confirm the findings in this regard. Finally, some of the CDSM strategies used in this study were not  
295 precisely defined. For example, a regular schedule did not limit the sleep time per day or apply related  
296 scales to measure sleep quality, which may have led to some imprecision. In future studies, we will  
297 further quantify the strategies addressed in this study to obtain more effective CDSM strategies for  
298 patients with CHF.

## 299 **5 Conclusions**

300 This study observed an association of avoidance of over-eating and maintenance of a regular  
301 schedule with the improvement of CHF-PROM. Among them, only the strategies happened often or  
302 every day had the clinical significance. It prompts patients and physicians to give preference to certain  
303 strategies and enables them to understand more intuitively and profoundly the meaning of measure  
304 compliance.

305

306

307 **List of abbreviations**

308 CCI: Charlson Comorbidity Index; CDSM: chronic disease self-management; CHF: Chronic heart  
309 failure; CHF-PROM: chronic heart failure - patient-reported outcome measure; HF: heart failure;  
310 KCCQ: Kansas City Cardiomyopathy Questionnaire; LSD: low-sodium diet; MCID: minimal clinically  
311 important difference; NYHA: New York Heart Association; OS: overall summary; PHYS: physical  
312 scores; PRO: Patient-reported outcome; PSYS: psychological scores; QoL: quality of life; SD: standard  
313 deviation.

314

315 **Declarations**

316 **Ethics approval and consent to participate**

317 This study was reviewed and approved by the Institutional Review Board of Shanxi Medical  
318 University. All procedures performed were in accordance with the ethical standards of the institutional  
319 and/or national research committee and with the 1964 Helsinki declaration and its later amendments or  
320 comparable ethical standards. Patients were informed verbally and in writing about the study and gave  
321 written informed consent.

322 **Consent for publication**

323 All authors have approved the manuscript for publication.

324 **Availability of data and material**

325 The datasets used and/or analyzed during the current study are available from the corresponding  
326 author on reasonable request.

327 **Competing interests**

328 The authors declare that they have no competing interests.

329 **Funding**

330 This research was funded by the National Nature Science Foundation of China (Grant No.  
331 81872714), the General Program for Young Scholar of Shanxi Province (Grant No. 201801D221423)  
332 and key projects of Shanxi Province (Grant No. 2016YFC090310 and YDZX20191400004850).

333 **Authors' contributions**

334 All authors participated in the study design. JT was responsible for collecting the data and drafting  
335 the article. QZ, JR and LH participated in the data collection and modified the article. JZ and JL  
336 participated in the data analysis and modified the article. QH and YZ proposed the original concept for  
337 this study, supervised the data analysis, and revised the paper. All authors read and approved the final  
338 manuscript.

339 **Acknowledgments**

340 We are grateful for the cooperation of Shanxi Cardiovascular Hospital and Shanxi Bethun  
341 Hospital.

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357 **References**

- 358 1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC / AHA /  
359 HFSA focused update of the 2013 ACCF / AHA guideline for the management of heart failure: a  
360 report of the American College of Cardiology / American Heart Association Task Force on  
361 Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017; 136(6):  
362 137-161.
- 363 2. Hu S, Gao R, Liu L, Zhu M, Wang W, Wang Y, et al. Summary of the 2018 Report on  
364 Cardiovascular Diseases in China. *Chinese Circulation Journal*. 2019; 34(3): 209-220.
- 365 3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines  
366 for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis  
367 and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)  
368 Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur.*  
369 *Heart J*. 2016; 37(27): 2129-2200.
- 370 4. U.S. Department of Health and Human Services FDA Center for drug evaluation and research, U.S.  
371 Department of Health and Human Services FDA Center for biologics evaluation and research, U.S.  
372 Department of Health and Human Services FDA Center for devices and radiological health.  
373 Guidance for industry: patient-reported outcome measures: use in medical product development to  
374 support labeling claims: draft guidance. *Health Qual Life Outcomes*. 2006; 4(79): e1-e20.
- 375 5. Kelkar AA, Spertus J, Pang P, Pierson RF, Cody RJ, Pina IL, et al. Utility of patient-reported  
376 outcome instruments in heart failure. *JACC Heart Fail*. 2016; 4(3): 165-175.
- 377 6. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al. Clinical  
378 practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient  
379 management. An expert consensus meeting report of the Heart Failure Association of the European  
380 Society of Cardiology. *Eur. J. Heart Fail*. 2019; 21(10): 1-17.

- 381 7. Jonkman NH, Westland H, Groenwold RH, Agren S, Atienza F, Blue L, et al. Do Self-Management  
382 Interventions Work in Patients With Heart Failure? An Individual Patient Data Meta-Analysis.  
383 *Circulation*. 2016; 133(12): 1189-1198.
- 384 8. Riegel B, Lee CS, Dickson VV, Medscape. Self care in patients with chronic heart failure. *Nat Rev*  
385 *Cardiol*. 2011; 8(11): 644-654.
- 386 9. Tian J, Xue J, Hu X, Han Q, Zhang Y. CHF-PROM: validation of a patient-reported outcome  
387 measure for patients with chronic heart failure. *Health Qual Life Outcomes*. 2018; 16(1): e1-e14.
- 388 10. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality  
389 of life in patients with advanced congestive heart failure[J]. *J Pain Symptom Manage*. 2008; 35(6):  
390 594–603.
- 391 11. Goldstein H. Multilevel statistical models. 3rd ed. Arnold. London. 2003.
- 392 12. Sedaghat AR. Understanding the Minimal Clinically Important Difference (MCID) of Patient-  
393 Reported Outcome Measures. *Otolaryngol Head Neck Surg*. 2019; 161(4): 1-10.
- 394 13. Wright A, Hannon J, Hegedus EJ, Kavchak AE. Clinimetrics corner: a closer look at the minimal  
395 clinically important difference (MCID). *J Man Manip Ther*. 2012; 20 (3): 160-166.
- 396 14. Carson P, Tam SW, Ghali JK, Archambault WT, Taylor A, Cohn JN, et al. Relationship of quality  
397 of life scores with baseline characteristics and outcomes in the African-American heart failure trial.  
398 *J. Card. Fail*. 2009; 15(10): 835-842.
- 399 15. Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, et al. Impact of Spironolactone  
400 on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac  
401 Function Heart Failure With an Aldosterone Antagonist Trial. *Circ Heart Fail*. 2016; 9(3): e1-9.
- 402 16. Napier R, McNulty SE, Eton DT, Redfield MM, AbouEzzeddine O, Dunlay SM. Comparing  
403 Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection  
404 Fraction. *JACC Heart Fail*. 2018; 6(7): 552-560.
- 405 17. Broström A, Strömberg A, Dahlström U, Fridlund B. Sleep difficulties, daytime sleepiness, and  
406 health-related quality of life in patients with chronic heart failure. *J Cardiovasc Nurs*. 2004; 19(4):  
407 234-242.

- 408 18. Liu JC, Hung HL, Shyu YK, Tsai PS. The impact of sleep quality and daytime sleepiness on global  
409 quality of life in community-dwelling patients with heart failure. *J Cardiovasc Nurs.* 2011; 26(2):  
410 99-105.
- 411 19. F Johansson P, Dahlström U, Broström A. Factors and interventions influencing health-related  
412 quality of life in patients with heart failure: a review of the literature. *Eur J Cardiovasc Nurs.* 2006;  
413 5(1): 5-15.
- 414 20. Chang YL, Chiou AF, Cheng SM, Lin KC. Tailored educational supportive care programme on  
415 sleep quality and psychological distress in patients with heart failure: A randomised controlled trial.  
416 *Int J Nurs Stud.* 2016; 7(2): 219-229.
- 417 21. American Heart Association (2000) 'Heavy Meals May Trigger Heart Attacks.' *Science Daily.*
- 418 22. Cox HS, Kaye DM, Thompson JM, Turner AG, Jennings GL, Itsiopoulos C, et al. Regional  
419 sympathetic nervous activation after a large meal in humans. *Clin Sci (Lond).* 1995; 89(2): 145-  
420 154.
- 421 23. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al.  
422 Projected effect of dietary salt reductions on future cardiovascular disease. *N. Engl. J. Med.* 2010;  
423 362(7): 590-599.
- 424 24. Chen YW, Wang CY, Lai YH, Liao YC, Wen YK, Chang ST, et al. Home-based cardiac  
425 rehabilitation improves quality of life, aerobic capacity, and readmission rates in patients with  
426 chronic heart failure. *Medicine (Baltimore).* 2018; 97(4): 1-5.
- 427 25. Colin-Ramirez E, McAlister FA, Zheng Y, Sharma S, Armstrong PW, Ezekowitz JA. The long-  
428 term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The  
429 SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study. *Am.*  
430 *Heart J.* 2015; 169(2): 274-281.
- 431 26. Hummel SL, Karmally W, Gillespie BW, Helmke S, Teruya S, Wells J, et al. Home-Delivered  
432 Meals Postdischarge From Heart Failure Hospitalization. *Circ Heart Fail.* 2018; 11(8): 1-10.
- 433 27. Philipson H, Ekman I, Forslund HB, Swedberg K, Schaufelberger M. Salt and fluid restriction is  
434 effective in patients with chronic heart failure. *Eur. J. Heart Fail.* 2013; 15(11): 1304-1310.

435 28. Welsh D, Lennie TA, Marcinek R, Biddle MJ, Abshire D, Bentley B, et al. Low-sodium diet self-  
436 management intervention in heart failure: pilot study results. *Eur J Cardiovasc Nurs.* 2013; 12(1):  
437 87-95.

438 29. Chung ML, Park L, Frazier SK, Lennie TA. Long-Term Adherence to Low-Sodium Diet in Patients  
439 With Heart Failure. *West J Nurs Res.* 2017; 39(4): 1-15.

440 30. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of exercise-based  
441 cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and  
442 hospitalisation: an individual patient data meta-analysis of randomised trials. *Eur J Heart Fail.*  
443 2018; 20(12): 1735-1743.

444 31. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, et al. Impact of Exercise  
445 Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure: Individual Participant  
446 Meta-Analysis. *J. Am. Coll. Cardiol.* 2019; 73(12): 1430-1443.

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461 **Figure legends**

462 **Fig.1 Residual normality test diagram of OS** Figure (a) and figure (b) are the residual normality test  
463 graphs of OS at the different time points level and the individual level, respectively. The ordinates of  
464 the diagrams represent the standardized residuals of each level, and the abscissas are their normal  
465 fractions. The curve of each figure represents the residual normality test of each level. The residual is  
466 normally distributed when the curve performs as a straight line.

467 **Fig. 2 Residual normality test diagram of PHYS and PSYS** Figure (a) and figure (b) represent the  
468 residual normality tests of PHY at the timepoint level and the individual level, respectively. Figure (c)  
469 and figure (d) represent the residual normality test of PSY at the time-point level and the individual  
470 level, respectively.

471 **Fig. 3 Comparison of MCID to the cumulative  $\beta$  for variables** Each point represents the value that  
472 the correspond  $\beta$  of strategy multiplied by (grade-1). MCID is shown as a dotted black line. The  
473 strategy is of the clinical significance when the its value is larger than MCID. Figure (a) represents the  
474 influence of management strategies on OS. Figure (b) and (c) represent the influence of management  
475 strategies on PHY and PSY, respectively.

476

477

478

479

480

481

482

483

484

485